We are live on
!
Find out more
PCA
Private Capital Advisors Portfolio holdings
AUM
$1.15B
Turnover
18.82%
1-Year Est. Return
43.46%
This Fund
S&P 500
This Quarter
Est. Return
+10.64%
1 Year Est. Return
+43.46%
3 Year Est. Return
+131.91%
5 Year Est. Return
+229.29%
10 Year Est. Return
+757.55%
AUM
$269M
AUM Growth
–
Cap. Flow
+$264M
Cap. Flow
% of AUM
98.02%
Top 10 Holdings %
Top 10 Hldgs %
27.65%
Holding
112
New
112
Increased
–
Reduced
–
Closed
–
Avg Time Held
0
years
Top 10 Avg Time Held
0
years
Top 20 Avg Time Held
0
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celldex Therapeutics
CLDX
|
+$10.8M |
| 2 |
RH
RH
|
+$10.3M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$7.56M |
| 4 |
Apple
AAPL
|
+$6.29M |
| 5 |
Enterprise Products Partners
EPD
|
+$6.18M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.57% |
| 2 | Energy | 19.28% |
| 3 | Communication Services | 12.18% |
| 4 | Industrials | 9.72% |
| 5 | Technology | 7.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Charter Communications
CHTR
$12.7B
| $644K | 0.24% |
+5,200
| New | +$571K |
2013 Q2
0 quarters
|
|
77
Microsoft
MSFT
$3.92T
| $514K | 0.19% |
+14,875
| New | +$487K |
2013 Q2
0 quarters
|
|
78
American Electric Power
AEP
$69B
| $483K | 0.18% |
+10,790
| New | +$518K |
2013 Q2
0 quarters
|
|
79
CVS Health
CVS
$118B
| $483K | 0.18% |
+8,450
| New | +$490K |
2013 Q2
0 quarters
|
|
80
Invesco QQQ Trust
QQQ
$477B
| $479K | 0.18% |
+6,720
| New | +$480K |
2013 Q2
0 quarters
|
|
81
GE Aerospace
GE
$329B
| $459K | 0.17% |
+4,132
| New | +$457K |
2013 Q2
0 quarters
|
|
82
Oracle
ORCL
$392B
| $447K | 0.17% |
+14,555
| New | +$483K |
2013 Q2
0 quarters
|
|
83
T. Rowe Price
TROW
$21.4B
| $434K | 0.16% |
+5,930
| New | +$443K |
2013 Q2
0 quarters
|
|
|
DISH
84
DELISTED
DISH Network Corp.
DISH
| $434K | 0.16% |
+10,200
| New | +$397K |
2013 Q2
0 quarters
|
|
85
Ball Corp
BALL
$16.7B
| $418K | 0.16% |
+20,120
| New | +$452K |
2013 Q2
0 quarters
|
|
|
HPTX
86
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
| $396K | 0.15% |
+18,001
| New | +$394K |
2013 Q2
0 quarters
|
|
87
Merck
MRK
$363B
| $395K | 0.15% |
+8,908
| New | +$398K |
2013 Q2
0 quarters
|
|
88
Intuit
INTU
$86.1B
| $375K | 0.14% |
+6,150
| New | +$372K |
2013 Q2
0 quarters
|
|
|
VIAB
89
DELISTED
Viacom Inc. Class B
VIAB
| $374K | 0.14% |
+5,500
| New | +$366K |
2013 Q2
0 quarters
|
|
90
Parker-Hannifin
PH
$122B
| $356K | 0.13% |
+3,727
| New | +$349K |
2013 Q2
0 quarters
|
|
91
Walmart Inc
WMT
$944B
| $324K | 0.12% |
+13,065
| New | +$335K |
2013 Q2
0 quarters
|
|
92
Bristol-Myers Squibb
BMY
$124B
| $317K | 0.12% |
+7,097
| New | +$308K |
2013 Q2
0 quarters
|
|
93
Procter & Gamble
PG
$368B
| $308K | 0.11% |
+4,000
| New | +$314K |
2013 Q2
0 quarters
|
|
|
PT
94
DELISTED
PORTUGAL TELECOM SGPS, S.A.
PT
| $293K | 0.11% |
+74,500
| New | +$350K |
2013 Q2
0 quarters
|
|
95
Fiserv Inc
FISV
$25.3B
| $267K | 0.1% |
+12,200
| New | +$268K |
2013 Q2
0 quarters
|
|
|
LLL
96
DELISTED
L3 Technologies, Inc.
LLL
| $257K | 0.1% |
+3,000
| New | +$252K |
2013 Q2
0 quarters
|
|
97
Consolidated Edison
ED
$41.4B
| $254K | 0.09% |
+4,350
| New | +$261K |
2013 Q2
0 quarters
|
|
98
Cencora
COR
$65.1B
| $248K | 0.09% |
+4,436
| New | +$241K |
2013 Q2
0 quarters
|
|
99
DELISTED
Hess
HES
| $239K | 0.09% |
+3,600
| New | +$249K |
2013 Q2
0 quarters
|
|
100
Goldman Sachs
GS
$257B
| $216K | 0.08% |
+1,425
| New | +$217K |
2013 Q2
0 quarters
|
|
Similar funds
WB
AIC
CFP
HT
AA
CIG
CIS
FWM
Private Capital Advisors's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Private Capital Advisors, which disclosed 112 positions worth $269M. Its ten largest holdings account for 28% of the portfolio.
Its largest position is Celldex Therapeutics: 54,837 shares worth $12.8M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, followed by Energy and Communication Services.
- Private Capital Advisors's largest Q2 2013 buy was Celldex Therapeutics: 54,837 shares worth $12.8M.
- Private Capital Advisors's ten largest holdings make up 28% of its $269M portfolio in Q2 2013.
- Private Capital Advisors disclosed 112 positions in Q2 2013, its first 13F filing on record.
Based on Private Capital Advisors's 13F filing for Q2 2013, filed 24 Jul 2013.